PubRank

D Pometta

Author PubWeight™ 33.28‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994 2.04
2 Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993 1.57
3 Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta 1995 1.16
4 Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994 1.15
5 Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res 1989 1.09
6 Asymptomatic bacteriuria in diabetes mellitus. N Engl J Med 1967 1.05
7 Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci U S A 1988 1.00
8 Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes 1990 0.96
9 Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia 1981 0.95
10 Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. Arterioscler Thromb 1991 0.94
11 Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. J Lipid Res 1988 0.90
12 Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. Int J Clin Pharmacol Biopharm 1979 0.85
13 [Dyslipidemia in the diabetic patient. Recommendations of ALFEDIAM (French Language Association for the Study of Diabetes and Metabolic Diseases)]. Diabete Metab 1995 0.85
14 Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia 1995 0.83
15 Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. Biochim Biophys Acta 1989 0.82
16 Liver glycerokinase deficiency in man with hyperglycerolaemia and hypertriglyceridaemia. Eur J Clin Invest 1984 0.81
17 Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications. Biochim Biophys Acta 1991 0.81
18 Iron excess, early glucose intolerance and impaired insulin secretion in idiopathic haemochromatosis. Eur J Clin Invest 1973 0.81
19 HDL lipids in close relatives of coronary heart disease patients. Environmental and genetic influences. Atherosclerosis 1979 0.81
20 HDL particle associated proteins in plasma and cerebrospinal fluid: identification and partial sequencing. Appl Theor Electrophor 1988 0.81
21 Metabolic effects of dietary fiber from dehulled soybeans in humans. Am J Clin Nutr 1983 0.80
22 Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations. Atherosclerosis 1990 0.80
23 [Apoprotein E (apo E) phenotype and serum lipids in diabetics]. Schweiz Med Wochenschr 1987 0.79
24 Phenotyping is an accurate means of analysing the principal apolipoprotein E isoforms. Clin Chim Acta 1994 0.78
25 Postprandial lipemia differentially influences high density lipoprotein subpopulations LpAI and LpAI,AII. J Lipid Res 1994 0.78
26 High density lipoprotein cholesterol in male relatives of patients with coronary heart disease. Atherosclerosis 1979 0.78
27 The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991 0.78
28 Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care 1995 0.78
29 Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb 1993 0.77
30 Factors influencing the low density lipoprotein profile in type 2 diabetic patients. Diabet Med 1995 0.77
31 HDL and coronary heart disease: a familial trend. Adv Exp Med Biol 1987 0.77
32 Acquired (secondary) forms of hypertriglyceridemia. Am J Cardiol 1991 0.77
33 Apoprotein D in a healthy, male population and in male myocardial infarction patients and their male, first-degree relatives. Atherosclerosis 1986 0.77
34 HDL cholesterol levels in patients with myocardial infarction and their families. Atherosclerosis 1986 0.76
35 Gender differences in a type 2 (non-insulin-dependent) diabetic population with respect to apolipoprotein E phenotype frequencies. Diabetologia 1993 0.76
36 Decreased HDL cholesterol in prepubertal and pubertal children of CHD patients. Atherosclerosis 1980 0.76
37 Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol 1994 0.75
38 Marked changes of lipid levels during puberty in a patient with lipoprotein lipase deficiency. Eur J Pediatr 1997 0.75
39 Interference of dimethyl alpha-(dimethoxyphosphinyl) p-chlorobenzyl phosphate (SR-202) in thyroid hormone metabolism: evidence of inhibition of monodeiodination. J Endocrinol 1987 0.75
40 [Hypercholesteremia: a problem of daily practice]. Rev Med Suisse Romande 1968 0.75
41 [Diet in the treatment of hyperlipidaemia (author's transl)]. Ther Umsch 1980 0.75
42 [The development of an extensive dissecting aneurysm of the aorta]. Rev Med Suisse Romande 1965 0.75
43 [The clinical importance of cardiovascular risk factors]. Schweiz Rundsch Med Prax 1992 0.75
44 [Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions]. Helv Med Acta Suppl 1967 0.75
45 [Diagnosis and treatment of hyperlipoproteinemias]. Schweiz Med Wochenschr 1972 0.75
46 Early capillary changes in diabetes mellitus. Acta Diabetol Lat 1971 0.75
47 [HDL and lipoproteins in the families of coronary patients]. Schweiz Med Wochenschr 1981 0.75
48 Immunological confirmation of the presence of NA1/NA2 (cytolysis inhibitor) in cerebrospinal fluid. Schweiz Arch Neurol Psychiatr 1991 0.75
49 Topical timolol maleate might adversely affect serum lipoproteins. Int Ophthalmol 1993 0.75
50 [High-density lipoproteins in children with coronary diseases]. Helv Paediatr Acta 1981 0.75
51 The influence of metabolic control on very low density lipoprotein composition in hypertriglyceridemic type II diabetics. A study using heparin-sepharose chromatography. Metabolism 1988 0.75
52 Clofibrate, nephrotic syndrome, and histological changes in muscle. Lancet 1973 0.75
53 [Hyperlipemia and diabetes]. Schweiz Med Wochenschr 1976 0.75
54 Apparent lack of influence of the genetic drug oxidation status on plasma cholesterol concentration in man. Pharmacol Res Commun 1984 0.75
55 [Dyslipidemias and diabetes mellitus]. Journ Annu Diabetol Hotel Dieu 1989 0.75
56 Preparative isoelectrofocusing and high resolution 2-dimensional gel electrophoresis for concentration and purification of proteins. Appl Theor Electrophor 1991 0.75
57 Geneva study on the precursors of atherosclerosis: first results. Soz Praventivmed 1979 0.75
58 Lipoprotein complexes in human cerebrospinal fluid. Schweiz Arch Neurol Psychiatr 1993 0.75
59 [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)]. Schweiz Med Wochenschr 1993 0.75
60 [Coronary insufficiency, hyperlipemia and diabetes]. Journ Annu Diabetol Hotel Dieu 1976 0.75
61 [Low HDL cholesterol in close relatives and patients with myocardial infarct]. Schweiz Med Wochenschr 1978 0.75
62 High density lipoprotein (HDL) subfractions in cardiovascular patients with low levels of HDL-cholesterol. Influence of hypertriglyceridaemia on subfraction concentration and composition. Atherosclerosis 1988 0.75
63 Actin stress fiber content of regenerated endothelial cells correlates with intramural retention of intermediate plus low density lipoproteins in rat aorta after balloon injury. Atherosclerosis 1989 0.75
64 [Serum lipoproteins in family members of myocardial infarct victims]. Soz Praventivmed 1978 0.75
65 [Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions]. Helv Med Acta 1967 0.75
66 [Clinical study on the relationship between diabetes, hyperlipoproteinemia and atheromatosis]. Schweiz Med Wochenschr 1973 0.75
67 [Teaching and Treatment Unit in the Division of Diabetology (Geneva)]. Rev Med Suisse Romande 1980 0.75
68 [Coronary atherosclerosis and serum lipoproteins]. Schweiz Med Wochenschr 1979 0.75
69 [Classification of hyperlipoproteinemia in the light of advances in pathogenetic studies]. Pol Tyg Lek 1985 0.75
70 A novel high-density lipoprotein particle and associated protein in rat plasma. Biochim Biophys Acta 1990 0.75
71 [Relation between HDL cholesterol and fasting glycemia in a normal population and a diabetic group]. Schweiz Med Wochenschr 1984 0.75
72 [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)]. Nouv Presse Med 1980 0.75
73 [Influence of hormonal contraception on serum lipoproteins]. Schweiz Med Wochenschr 1978 0.75
74 [Cholesterol and triglycerides of serum lipoproteins isolated by means of ultracentrifugation. Correlation with arteriosclerosis]. Schweiz Med Wochenschr 1974 0.75
75 Lipid, lipoprotein and APO-A and APO-B lipoprotein distribution in Italian and Swiss schoolchildren. The Geneva survey. Pediatr Res 1982 0.75
76 [Dietary treatment of the hyperlipidemias]. Ther Umsch 1986 0.75
77 [Procetofen in the treatment of hyperlipoproteinaemias (author's transl)]. Schweiz Rundsch Med Prax 1980 0.75
78 [The general practitioner confronted with hypercholesteremia]. Schweiz Rundsch Med Prax 1970 0.75
79 [Drug therapy of hyperlipemia. Role of drugs at the disposition of general practitioners]. Ther Umsch 1970 0.75
80 [Drug therapy of hyperlipoproteinemias]. Ther Umsch 1980 0.75
81 Treatment of systemic lupus erythematosus (SLE) with immunosuppressive drugs 1: An analysis of immunologic data. Helv Med Acta 1967 0.75
82 [HDL-cholesterol and family incidence of coronary disease in the Genevan population]. Schweiz Med Wochenschr 1983 0.75
83 [Diabetic microangiopathy, early or late manifestation of the disease? Electron microscopy study of muscular capillaries]. Helv Med Acta Suppl 1970 0.75
84 Diabetic retinopathy: study of the action of O-betahydroxyethyl-rutosides (HR) by retinal fluoresceinography. Diabetologia 1970 0.75
85 Capillary basement membrane thickness in early diabetes. Adv Metab Disord 1973 0.75
86 [Molecular pathophysiology of familial hypercholesterolemia]. Pol Tyg Lek 1985 0.75
87 [Dyslipidemias and atherosclerosis. Treatment strategy]. Schweiz Rundsch Med Prax 1986 0.75
88 [Remnant disease associated with apoprotein E1; clinical importance of apoprotein E (apo E) phenotypes]. Schweiz Med Wochenschr 1989 0.75
89 [Effect of renal insufficiency on diabetes mellitus]. Rev Med Suisse Romande 1979 0.75
90 [Reversible acquired acanthocytosis and hemolytic anemia associated with hypobetalipoproteinemia in a chronic alcoholic]. Schweiz Med Wochenschr 1983 0.75
91 [Diabetic retinopathy: study on the action of l'o-beta-hydroxyethylrutoside for retinal fluoresceinography]. Helv Med Acta Suppl 1969 0.75
92 [Lipoprotein metabolism and atherosclerosis]. Schweiz Rundsch Med Prax 1988 0.75
93 [Study of glucose tolerance and insulin secretion (IRI) in familial hemochromatosis]. Helv Med Acta 1972 0.75
94 [Why change the fat content of diabetic diets?]. Rev Med Suisse Romande 1973 0.75
95 [Plasma lipoproteins. Influence of heredity and external factors in the genesis of dyslipidemias]. Rev Med Suisse Romande 1980 0.75
96 A non-competitive enzyme-linked immunosorbent assay for measuring human plasma apolipoprotein B levels. Clin Chim Acta 1985 0.75
97 [Vascular complications of diabetes]. Ther Umsch 1967 0.75
98 [Dyslipidemia in diabetes mellitus: significance, diagnosis and treatment]. Schweiz Rundsch Med Prax 1990 0.75
99 [Factors influencing the rate of elimination of injected fat emulsions (Intralipid) in healthy subjects and in patients with coronary disease]. Schweiz Med Wochenschr 1976 0.75
100 Epitope expression in purified and lipid-bound forms of human apoprotein A-I. Adv Exp Med Biol 1987 0.75
101 [Prediabetes and early diabetes]. Pol Tyg Lek 1966 0.75
102 [Dietary lipids and serum lipids in adolescents, based on the Geneva study of the precursors of atherosclerosis]. Soz Praventivmed 1984 0.75